
Publication|Articles|December 10, 2024
Evolving Treatment Strategies: Managing Advanced Prostate Cancer
Key Takeaways
Advertisement
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis
2
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
3
Gilteritinib Yields Comparable Efficacy vs Midostaurin in Newly Diagnosed FLT3-Mutated AML but Fails to Meet Phase 3 Primary End Point
4
Fixed-Duration Pirtobrutinib/Venetoclax/Rituximab Drives PFS Benefit in R/R CLL
5








































































